Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children
about
Protection of young children from influenza through universal vaccination.Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.Quadrivalent influenza vaccine in the United States.Available influenza vaccines: immunization strategies, history and new tools for fighting the disease.A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine.4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in GermanyCost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial.Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical TrialEpidemiological and Virological Characterization of Influenza B Virus Infections.Is the impact of childhood influenza vaccination less than expected: a transmission modelling studyInfluenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineageComparative Epidemiology of Influenza B Yamagata- and Victoria-Lineage Viruses in Households.Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden.Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approachKey issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination.Fluarix quadrivalent vaccine for influenza.Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: A double-blind, randomized, parallel-controlled phase III clinical trial in ChinaTime to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.[Quadrivalent influenza vaccines].Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.Forty five percent of the Israeli population were infected with the influenza B Victoria virus during the winter season 2015-16.Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
P2860
Q27693242-345029E2-BEA4-4B1B-AABF-C91EE3D01D01Q33609256-B5F17721-95F5-47A3-B9B2-D7248628BCFAQ34033810-F0715E65-D3AA-4BBC-9D2E-504DB5C4C073Q34532079-121513F9-1628-42E3-94D4-638E4AD30C7FQ35114177-180E2E62-C00F-4B3E-8BD2-9A43D2A2501AQ35200964-0B90206C-AECE-4279-AF6A-2728309C23FBQ35821862-AF1B749C-8C42-4472-84E6-4047F6561023Q35887773-ECC8AB1B-C6D6-49CA-9376-F934CA919E00Q36009631-7A55B65B-CBD0-4C55-B585-091F25C1C88DQ36105903-AF3E66FA-746A-437C-AAB6-FD79679F614CQ36343637-BB4679D1-F1B5-4CAE-8A58-90D38AEE114BQ36376605-FEA9D1A2-BBC1-455B-84FB-B82B093DFAA2Q36468830-92F22629-3DD2-43DA-87F8-91D1B38F93F7Q37011571-0455DA48-9B0D-4CDE-B255-72F87FBFF7D2Q37713755-B11DB8C4-84BF-406E-9DD3-1D57B5D6988AQ38204774-6B486834-C3DD-41CF-BDB4-7C41DF2ADB4DQ38534169-86545C4B-4CA8-4B4C-99A2-E5E2943CA5C4Q38660898-8CAC9085-2338-49D9-8E49-41E95255A7B5Q39322780-002577BC-EA2C-4CC1-8CBF-D3C5F01071D7Q40058830-6D490FB5-1EEE-440A-A4EB-60616F28BDD2Q40073913-A95D8BF3-41F8-43B5-B3E2-8454795243E3Q41389931-EA7492A3-91AB-4F23-8289-94965D6CC0FEQ41483739-2FD4BC9F-E2A7-4726-8B0E-665C9CB777ACQ49787340-A0D4761D-B218-4ADF-9260-46423E167C2CQ52579975-AF81CF68-C1B4-41E0-ABB2-52A0DBFD15E7
P2860
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenicity and safety of a ...... d controlled trial in children
@en
Immunogenicity and safety of a ...... controlled trial in children.
@nl
type
label
Immunogenicity and safety of a ...... d controlled trial in children
@en
Immunogenicity and safety of a ...... controlled trial in children.
@nl
prefLabel
Immunogenicity and safety of a ...... d controlled trial in children
@en
Immunogenicity and safety of a ...... controlled trial in children.
@nl
P2093
P2860
P50
P356
P1476
Immunogenicity and safety of a ...... d controlled trial in children
@en
P2093
Alfonso Carmona Martinez
Archana Chatterjee
Ching-Tien Peng
Consuelo Treviño-Garza
Fernando Cabañas
Ignacio Salamanca de la Cueva
José Garcia-Sicilia
Keith S Reisinger
Manuel de la O
P2860
P304
P356
10.1093/INFDIS/JIT263
P407
P50
P577
2013-07-11T00:00:00Z